Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Taiwan University Hospital |
---|---|
Information provided by: | National Taiwan University Hospital |
ClinicalTrials.gov Identifier: | NCT00155922 |
The investigators hypothesize that macrophages play a crucial role in the pathogenesis of atherosclerosis in patients with type 2 diabetes mellitus (T2DM).
Condition |
---|
Diabetes Mellitus, Type 2 Atherosclerosis |
Study Type: | Observational |
Study Design: | Natural History, Longitudinal, Case Control, Prospective Study |
Official Title: | The Gene Expression Patterns in the Peripheral White Blood Cells of Type 2 Diabetic Patients, Special Relevance to Atherosclerosis |
Estimated Enrollment: | 100 |
Study Start Date: | November 2003 |
Cardiovascular events are the leading cause of death in developed countries worldwide, including Taiwan. Type 2 diabetes mellitus (T2DM), previously considered merely as one of the risk factors, has been recently unanimously accepted to be coronary artery disease-equivalent. How T2DM may lead to accelerated atherosclerosis remains obscure. Hyperglycemia with or without hyperinsulinemia may lead to higher oxidative stress and generalized inflammation. The oxidative stress and inflammation may play a significant role in the pathogenesis in diabetic complications, including micro- and macro-vascular complications. Macrophages together with T-lymphocytes are the earliest cell-types found in fatty-streaks, the earliest atherosclerotic lesions. Macrophages are also well known cellular mediators of oxidative stress and inflammation. Therefore, it is plausible to hypothesize that macrophages play a crucial role in the pathogenesis of atherosclerosis in patients with T2DM. In addition, the other cell types of the peripheral white blood cells (WBC), such as neutrophils, have been shown to be intimately related to acute coronary syndrome. Therefore, the study on the biology of peripheral WBCs may tell us something about the pathophysiology of diabetic macro-vascular complications.
Methods:
T2DM: FPG >=126 mg/dl.
Ages Eligible for Study: | 25 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
T2DM: FPG >=126 mg/dl.
Exclusion Criteria:
Contact: Wei-Shiung Yang, MD, PhD | 886-2-2312-3456 ext 7258 | wsyang@ha.mc.ntu.edu.tw |
Taiwan | |
National Taiwan University Hospital | Recruiting |
Taipei, Taiwan, 10012 | |
Contact: Wei-Shiung Yang, MD, PhD 886-2-23123456 ext 7258 wsyang@ha.mc.ntu.edu.tw |
Principal Investigator: | Wei-Shiung Yang, MD, PhD | National Taiwan University Hospital |
Study ID Numbers: | 9261700953 |
Study First Received: | September 9, 2005 |
Last Updated: | December 13, 2006 |
ClinicalTrials.gov Identifier: | NCT00155922 History of Changes |
Health Authority: | Taiwan: Department of Health |
Diabetes mellitus Monocyte Gene expression Monocyte gene expression |
Arterial Occlusive Diseases Atherosclerosis Metabolic Diseases Diabetes Mellitus, Type 2 Vascular Diseases Diabetes Mellitus |
Endocrine System Diseases Endocrinopathy Arteriosclerosis Glucose Metabolism Disorders Metabolic Disorder |
Arterial Occlusive Diseases Atherosclerosis Metabolic Diseases Diabetes Mellitus, Type 2 Vascular Diseases |
Diabetes Mellitus Endocrine System Diseases Cardiovascular Diseases Arteriosclerosis Glucose Metabolism Disorders |